Search Results
May 27, 2026, 17:00 ET Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
metastatic GEA. The FDA granted two Breakthrough Therapy designations for zanidatamab's development: one as a single agent for previously treated HER2 gene-amplified BTC, and one in combination with fluoropyrimidine- and platinum-containing chemotherapy, with or without tislelizumab for first-line HER2+
More news about: Jazz Pharmaceuticals plc
May 27, 2026, 16:15 ET CPC Biotech Collaborates with Multiply Labs to Advance Cell Therapy Automation
accelerating patient access to advanced therapies," said Troy Ostreng, Senior Product Manager for CPC Biotech's biopharmaceutical and cell therapy and gene therapy (CGT) businesses. "To meet the growing need for faster, more efficient, high-quality cell therapy manufacturing, we're developing a first-ever
More news about: Dover
May 27, 2026, 08:31 ET Wet AMD Market Set for Robust Growth Through 2036, Driven by Advancements in Anti-VEGF Therapies | DelveInsight
AI-based diagnostic tools have significantly enhanced early detection and disease monitoring.Emerging Gene and Stem Cell Therapies Redefining Wet AMD Management: Emerging gene and stem cell therapies (e.g., RGX-314, Ixo-vec) offer durable, potentially one-time treatments for wet AMD, reducing
More news about: DelveInsight Business Research, LLP
May 27, 2026, 08:30 ET Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial
abstract highlights new preclinical data demonstrating that (Z)-endoxifen delivers robust ER inhibition across clinically relevant estrogen receptor alpha gene (ESR1) mutations. ESR1 mutations are a major mechanism of acquired endocrine resistance in ER-positive breast cancer and remain associated with limited
More news about: Atossa Therapeutics Inc
May 27, 2026, 08:00 ET Minaris Expands Rapid Mycoplasma Detection Services with bioMérieux's BIOFIRE® Platform to Reduce Turnaround Time for Release and In-Process Testing
timelines.PHILADELPHIA, May 27, 2026 /PRNewswire/ -- Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider, today announced an expanded rapid
More news about: Minaris Advanced Therapies, LLC
May 27, 2026, 08:00 ET TD2 Oncology and Panome Bio Partner to Advance Translational Oncology Through Integrated Multi-Omics Capabilities
technologies into this ecosystem, researchers can now connect therapeutic outcomes with broad molecular measurements spanning metabolism, protein signaling, gene expression, and environmental exposures. This combined approach supports biomarker discovery, mechanisms associated with sensitivity or resistance to
More news about: Panome Bio
May 27, 2026, 08:00 ET Biohub releases a world model of protein biology
proteins by relationships the model has learned, surfacing connections that existing databases have not captured, including evolutionary links between gene-editing enzymes spread across distant branches of life. Much of that biology has never been annotated. For researchers working on diseases where the
More news about: Biohub
May 27, 2026, 07:00 ET Nanoscope Therapeutics Selects InspiroGene by McKesson to Support Distribution of Novel Retinal Therapy
patients and providers as Nanoscope launches the first optogenetic gene therapy for the US market. "Nanoscope is advancing extraordinary science with a clear commitment to improving patients' lives," said Joe DePinto, Head of Cell, Gene, and Advanced Therapies at McKesson. "InspiroGene by McKesson is
More news about: Nanoscope Therapeutics
May 27, 2026, 07:00 ET Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference
therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue.Headquartered in Bridgewater, New Jersey, Insmed has offices and
More news about: Insmed Incorporated
May 27, 2026, 03:00 ET ARTHEx Biotech Delivers Multiple Presentations at IDMC-15 Highlighting Clinical Progress of ATX-01 and Mechanistic Insights for Myotonic Dystrophy Type 1 (DM1) and 2 (DM2)
HospitalMyotonic Dystrophy Type 2 is a multisystemic neuromuscular disease caused by the expansion of CCTG repeats within intron 1 of the CNBP gene, leading to the accumulation of toxic intronic RNA, sequestration of MBNL proteins into nuclear foci, and widespread splicing dysregulation. Despite
More news about: ARTHEx Biotech
May 27, 2026, 02:28 ET Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation
acute or complex immune disorders. Hansa's proprietary IgG-cleaving enzyme technology platform addresses serious unmet medical needs in transplantation, gene therapy and autoimmune diseases. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy,
More news about: Hansa Biopharma AB
May 27, 2026, 02:25 ET Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation
acute or complex immune disorders. Hansa's proprietary IgG-cleaving enzyme technology platform addresses serious unmet medical needs in transplantation, gene therapy and autoimmune diseases. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy,
More news about: Hansa Biopharma AB
May 26, 2026, 13:53 ET ATLANTIS PARADISE ISLAND, BAHAMAS COMEMORA O MÊS DO OCEANO MUNDIAL E DUAS DÉCADAS DE IMPACTO NA CONSERVAÇÃO MARINHA
lucrativos 501(c)3 do resort, dedicada à proteção de espécies marinhas e seus habitats. Realizações recentes incluem a curadoria contínua do primeiro Coral Gene Bank das Bahamas, a chegada de uma tartaruga marinha criticamente ameaçada após um resgate de 2.700 milhas e uma nova programação de convidados projetada
More news about: Atlantis, Paradise Island
May 26, 2026, 11:46 ET ATLANTIS PARADISE ISLAND, THE BAHAMAS COMMEMORATES WORLD OCEAN MONTH AND TWO DECADES OF MARINE CONSERVATION IMPACT
organization dedicated to protecting marine species and their habitats. Recent achievements include the ongoing curation of The Bahamas' first Coral Gene Bank, the arrival of a critically endangered sea turtle following a 2,700-mile rescue, and new guest programming designed to deepen understanding of
More news about: Atlantis, Paradise Island
May 26, 2026, 11:00 ET bitBiome Closes Oversubscribed Seed Extension Round
biomanufacturing," said Andrew Hyung of Valuence Ventures. "By combining proprietary single-cell microbial genome sequencing, one of the world's largest microbial gene databases, and AI-enabled enzyme discovery and engineering, bitBiome is unlocking microbial biodiversity that traditional approaches cannot reach and
More news about: bitBiome
May 26, 2026, 09:00 ET Orsini to Serve as Contracted Specialty Pharmacy for Gilead's Hepcludex® (bulevirtide‑gmod)
possible."About OrsiniProviding patients with comprehensive and compassionate care since 1987, Orsini is a leader in rare diseases and gene therapies. Orsini partners with biopharma innovators, healthcare providers and payors to support patients and their families in accessing revolutionary
More news about: Orsini
May 26, 2026, 09:00 ET Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
stratification for distant recurrence in node-positive ER+ /HER2- early breast cancer: Independent validation in the NSABP B-28 trialNeoadjuvant 21-gene Breast Recurrence Score redirects surgical and systemic treatment pathways in early breast cancer: a multicenter prospective studySystemic
More news about: Abbott
May 26, 2026, 08:00 ET Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting
receiving quaratusugene ozeplasmid"Abstract Number: e15184Quaratusugene ozeplasmid is a gene therapy that delivers a plasmid coding for the TUSC2 tumor suppressor gene to lung cancer cells, as >80% of lung cancers have been shown to have decreased or absent TUSC2 protein. TUSC2
More news about: Genprex, Inc.
May 26, 2026, 03:49 ET Global Times: Chinese, Bangladeshi, Pakistani researchers gather in Shanghai to breed better fish and closer ties
Global Times, "This curiosity eventually brought me to China."Tahir, also from Pakistan, has turned her attention to environmental stress and gene regulation, exploring how factors like heat and low oxygen can influence how fish grow, look and function. Tahir earned her PhD from Sichuan Agricultural
More news about: Global Times
May 26, 2026, 02:27 ET Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in South Korea for the preventive treatment of migraine
Approval granted by South Korea's Ministry of Food and Drug Safety (MFDS)Eptinezumab is an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody for the preventive treatment of migraine in adultsAuthorization supported by the Phase 3 SUNRISE trial conducted
More news about: H. Lundbeck A/S
May 25, 2026, 22:53 ET Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026
acute or complex immune disorders. Hansa's proprietary IgG-cleaving enzyme technology platform addresses serious unmet medical needs in transplantation, gene therapy and autoimmune diseases. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy,
More news about: Hansa Biopharma AB
May 25, 2026, 22:52 ET Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026
acute or complex immune disorders. Hansa's proprietary IgG-cleaving enzyme technology platform addresses serious unmet medical needs in transplantation, gene therapy and autoimmune diseases. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy,
More news about: Hansa Biopharma AB
May 25, 2026, 08:45 ET A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
a single-course treatment that turns off the PCSK9 gene in the liver and durably reduces disease-driving LDL-C. VERVE-102 consists of a messenger RNA encoding an adenine base editor and a guide RNA (gRNA) targeting the PCSK9 gene. Both are encapsulated in a lipid nanoparticle (LNP) and administered
More news about: Eli Lilly and Company
May 25, 2026, 08:03 ET Menarini Group Anuncia Novos Dados na Reunião Anual da American Society of Clinical Oncology (ASCO) 2026
randomizado, duplo-cego de fase 3 que avalia o elacestranto em combinação com everolimus em pacientes com CMm ER+, HER2- com tumores por mutação no gene ESR1. ELEVATE (NCT05563220) é um ensaio clínico de fase
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 05:51 ET MGI Tech Secures Three iF Design Awards for Breakthrough in Sequencing and Ultrasound
tools and technologies that drive innovation in life sciences, is proud to announce that three of its latest innovations—the T1+ and T7+ gene sequencers and the Imabot™ EF6-CL handheld ultrasound—have been honored with the prestigious iF Design Award. Recognized for merging cutting-edge
More news about: MGI Tech Co., Ltd.